Sugi Predict

Sugi Predict / Compounds / SCHEMBL2256351

SCHEMBL2256351

SCHEMBL2256351

Cl[Zn]Cc1cccc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 2/20 0.58
▸ TAAR1 Q96RJ0 3/20 0.54
▸ CYP3A4 P08684 2/20 0.52
▸ IDO1 P14902 2/20 0.52
▸ AGXT P21549 2/20 0.52
▸ HTR3E A5X5Y0 3/20 0.48
▸ HTR3B O95264 3/20 0.48
▸ HTR3A P46098 3/20 0.48
▸ HTR3D Q70Z44 3/20 0.48
▸ HTR3C Q8WXA8 3/20 0.48
▸ MAOB P27338 2/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.47
▸ AOC3 Q16853 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL541737 0.85 PNMT (0.44) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL1301622 0.79 PNMT (0.56) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL2216304 0.79 PNMT (0.56) PNMTTAAR1CYP3A4IDO1AGXT
Bromide SCHEMBL1301106 0.77 PNMT (0.54) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL3300276 0.77 PNMT (0.65) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL12050856 0.77 TAAR1 (0.74) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL2803352 0.76 IDO1 (0.58) PNMTTAAR1CYP3A4IDO1AGXT
SCHEMBL195102 0.75 — —
SCHEMBL30181552 0.75 — —
SCHEMBL29355341 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 — — WO claimed
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 — — WO disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 — — US disclosed
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 — — US disclosed
US-20230078764-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 — — US disclosed
US-20230024438-A1 INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. 2023-01-26 — — US disclosed
US-20220331316-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2022-10-20 — — US disclosed
EP-4069212-A1 INHIBITORS OF HIF-2ALPHA Arcus Biosciences, Inc. (US) 2022-10-12 — — EP disclosed
US-20220298168-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2022-09-22 — — US disclosed
EP-3368036-B1 MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-07-20 — — EP disclosed
EP-1740211-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-01-10 — — EP disclosed
EP-1682510-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION Wyeth (US) 2006-07-26 — — EP disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 — — EP disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
WO-2005047258-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION WYETH (US) 2005-05-26 — — WO disclosed
US-20050101569-A1 Methods and compositions for selectin inhibition WYETH (US) 2005-05-12 — — US disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 — — US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 — — WO disclosed
US-20040267011-A1 Methods for synthesis of diarylmethanes DANA-FARBER CANCER INSTITUTE 2004-12-30 — — US disclosed
WO-2003031458-A1 METHODS FOR SYNTHESIS OF DIARYLMETHANES DANA-FARBER CANCER INSTITUTE (US) 2003-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267011-A1 Methods for synthesis of diarylmethanes DHFR, DPYD, DHODH PNMT 300/4885TAAR1 1128/4885CYP3A4 92/4885
US-20230078764-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 PNMT 30/4885TAAR1 3815/4885CYP3A4 1707/4885
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 PNMT 4062/4885TAAR1 4340/4885CYP3A4 441/4885
US-20050101569-A1 Methods and compositions for selectin inhibition SELP, SELE, SELL PNMT 764/4885TAAR1 2776/4885CYP3A4 2021/4885
US-20220298168-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PNMT 57/4885TAAR1 2733/4885CYP3A4 1178/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 PNMT 57/4885TAAR1 2733/4885CYP3A4 1178/4885
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 PNMT 1779/4885TAAR1 1368/4885CYP3A4 221/4885
US-20220331316-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 PNMT 4062/4885TAAR1 4340/4885CYP3A4 441/4885
US-20230024438-A1 INHIBITORS OF HIF-2ALPHA HIF1AN, HIF1A, EGLN2 PNMT 4339/4885TAAR1 4708/4885CYP3A4 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.